Use of PPI pre endoscopy in acute GI bleeding
Date First Published:
July 17, 2026
Last Updated:
July 17, 2026
Report by:
Malik awan, Momina Shafique, SPR, CF (TAMESIDE AND GLOSSOP NHS TRUST)
Search checked by:
Malik Awan, SPR
Three-Part Question:
In patients with upper GI Bleed use of IV PPI pre endoscopy Improve outcomes
Clinical Scenario:
A patient presents to the Emergency Department with acute upper gastrointestinal bleeding and is awaiting endoscopy. Intravenous proton pump inhibitor therapy is commenced before endoscopic evaluation. The treating team questions whether administration of PPI therapy before endoscopy improves patient outcomes compared with no pre-endoscopic PPI therapy
Search Strategy:
MEDLINE (via PubMed), Embase, BMJ and Cochrane Library searched from inception to June 2026.
Search Details:
MEDLINE (via PubMed), Embase, and Cochrane Library searched from inception to June 2026.
Search terms:
("upper gastrointestinal bleeding" OR "upper GI bleed" OR "non-variceal upper gastrointestinal haemorrhage" OR "peptic ulcer bleeding") AND ("proton pump inhibitor" OR Omeprazole OR Pantoprazole OR Esomeprazole OR Lansoprazole) AND ("pre-endoscopic" OR "before endoscopy" OR "Prior to endoscopy" AND (randomized controlled trial OR systematic review OR meta-analysis).
Limits: Human studies, adults, English language.
Search terms:
("upper gastrointestinal bleeding" OR "upper GI bleed" OR "non-variceal upper gastrointestinal haemorrhage" OR "peptic ulcer bleeding") AND ("proton pump inhibitor" OR Omeprazole OR Pantoprazole OR Esomeprazole OR Lansoprazole) AND ("pre-endoscopic" OR "before endoscopy" OR "Prior to endoscopy" AND (randomized controlled trial OR systematic review OR meta-analysis).
Limits: Human studies, adults, English language.
Outcome:
A number of studies were identified. The highest level of evidence consisted of a Cochrane systematic review including six randomized controlled trials involving 2,223 patients. Additional landmark randomized controlled trials were reviewed. Studies examining post-endoscopic PPI therapy only were excluded.
Relevant Papers
Author, Year Patient Group Study Type Outcomes Key Results Weaknesses
Lau et al., 2007 Patients with acute upper GI bleeding awaiting endoscopy Randomised controlled trial High-risk stigmata, endoscopic therapy, mortality, rebleeding Reduced high-risk stigmata and need for endoscopic therapy; no significant mortality benefit Single healthcare system
Sreedharan et al. (Cochrane Review, updated 2022) 2,223 patients from 6 RCTs Systematic review and meta-analysis Mortality, rebleeding, surgery, endoscopic therapy No significant reduction in mortality, rebleeding or surgery; reduction in need for endoscopic haemostatic treatment Moderate heterogeneity between studies
Additional RCTs included in Cochrane review Acute non-variceal UGIB Randomised controlled trials Clinical outcomes Consistent reduction in endoscopic stigmata; no clear improvement in major patient-centred outcomes
Relevant Papers
Author, Year Patient Group Study Type Outcomes Key Results Weaknesses
Lau et al., 2007 Patients with acute upper GI bleeding awaiting endoscopy Randomised controlled trial High-risk stigmata, endoscopic therapy, mortality, rebleeding Reduced high-risk stigmata and need for endoscopic therapy; no significant mortality benefit Single healthcare system
Sreedharan et al. (Cochrane Review, updated 2022) 2,223 patients from 6 RCTs Systematic review and meta-analysis Mortality, rebleeding, surgery, endoscopic therapy No significant reduction in mortality, rebleeding or surgery; reduction in need for endoscopic haemostatic treatment Moderate heterogeneity between studies
Additional RCTs included in Cochrane review Acute non-variceal UGIB Randomised controlled trials Clinical outcomes Consistent reduction in endoscopic stigmata; no clear improvement in major patient-centred outcomes
Author Commentary:
The rationale for pre-endoscopic PPI therapy is that increasing gastric pH promotes clot stability and may downstage the appearance of bleeding peptic ulcers before endoscopy. The available evidence demonstrates that PPIs administered before endoscopy reduce the proportion of patients with high-risk endoscopic stigmata and decrease the need for endoscopic haemostatic intervention.
However, the evidence does not demonstrate a significant reduction in mortality, recurrent bleeding, need for surgery, or blood transfusion requirements. While pre-endoscopic PPI therapy appears safe and may simplify endoscopic management, its benefits are largely confined to endoscopic outcomes rather than major clinical outcomes.
Current practice guidelines vary slightly in their recommendations. Some support the use of PPI therapy when endoscopy is delayed, whereas others advise against routine pre-endoscopic acid suppression because of the lack of demonstrated benefit in patient-centred outcomes. There is broad agreement that PPI administration should never delay urgent endoscopic assessment.
However, the evidence does not demonstrate a significant reduction in mortality, recurrent bleeding, need for surgery, or blood transfusion requirements. While pre-endoscopic PPI therapy appears safe and may simplify endoscopic management, its benefits are largely confined to endoscopic outcomes rather than major clinical outcomes.
Current practice guidelines vary slightly in their recommendations. Some support the use of PPI therapy when endoscopy is delayed, whereas others advise against routine pre-endoscopic acid suppression because of the lack of demonstrated benefit in patient-centred outcomes. There is broad agreement that PPI administration should never delay urgent endoscopic assessment.
Bottom Line:
Pre-endoscopic proton pump inhibitor therapy in suspected non-variceal upper gastrointestinal bleeding reduces the prevalence of high-risk endoscopic stigmata and decreases the need for endoscopic haemostatic intervention. Current evidence does not demonstrate a reduction in mortality, recurrent bleeding, or need for surgery. Administration of a PPI may be considered while awaiting endoscopy but should not delay definitive endoscopic management.
Level of Evidence:
Level 1: Recent well-done systematic review was considered or a study of high quality is available